Since Novo Nordisk was founded more than 90 years ago, we have been changing diabetes. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Our ambition is to take the lead in each of these areas, driving change with an unfailing belief that it can be done.
Mads Krogsgaard Thomsen, CSO of Novo Nordisk, considers the potential of stem cell-based therapies to cure type 1 diabetes and other chronic diseases
Head of Global Drug Discovery Marcus Schindler and Head of diabetes and stem cell research Jacob Sten Petersen shares insights into increased commitment to stem cell-based therapies.
Scientific Vice President Lotte Bjerre Knudsen talks about her experiences of taking an underdog molecule to a treatment for millions of people with diabetes and obesity
Chief Science Officer Mads Krogsgaard Thomsen reflects on the past, present and future of insulin in a tablet.
We believe that partnerships are key to fostering innovation.
We are guided by the principle that a patient centered approach to our business must be informed by input from patients and win-win partnerships. Therefore, we work in partnership with a network called the Disease Experience Expert Panels (DEEPs).